Autoimmunity checkpoints as therapeutic targets in B cell malignancies

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• Targeted cancer therapy typically uses inhibitors to suppress oncogenic signaling.
• B cell malignancies originate from B cells, which undergo intense selection.
• Autoreactive B cells are normally eliminated by autoimmunity checkpoints (AICs) due to strong B cell receptor (BCR) signaling.

Purpose of the Study:

• To propose targeted engagement of autoimmunity checkpoints (AICs) as a novel therapeutic strategy.
• To address drug resistance in B cell malignancies.
• To highlight a previously unrecognized therapeutic opportunity.

Main Methods:

• This is an opinion article based on recent findings.
• It reviews the functional status of AICs in B cell malignancies.
• It proposes a new therapeutic approach.

Main Results:

• Recent findings suggest that AICs remain functional in B cell malignancies.
• Targeted engagement of AICs could be a viable therapeutic strategy.
• This approach may overcome drug resistance.

Conclusions:

• Autoimmunity checkpoints (AICs) are fully functional in B cell malignancies.
• Targeting AICs offers a novel therapeutic avenue.
• This strategy holds promise for overcoming drug resistance in B cell cancers.